156 related articles for article (PubMed ID: 34420030)
1. Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.
Fiori LM; Orri M; Aouabed Z; Théroux JF; Lin R; Nagy C; Frey BN; Lam RW; MacQueen GM; Milev R; Müller DJ; Parikh SV; Rotzinger S; Uher R; Foster JA; Kennedy SH; Turecki G
Transl Psychiatry; 2021 Aug; 11(1):439. PubMed ID: 34420030
[TBL] [Abstract][Full Text] [Related]
2. Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.
Ju C; Fiori LM; Belzeaux R; Theroux JF; Chen GG; Aouabed Z; Blier P; Farzan F; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Milev R; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Uher R; Li Q; Foster JA; Kennedy SH; Turecki G
Transl Psychiatry; 2019 Oct; 9(1):254. PubMed ID: 31594917
[TBL] [Abstract][Full Text] [Related]
3. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
5. Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.
Espinola CW; Khoo Y; Parmar R; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V
J Psychopharmacol; 2022 May; 36(5):604-613. PubMed ID: 35546043
[TBL] [Abstract][Full Text] [Related]
6. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
[TBL] [Abstract][Full Text] [Related]
7. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
9. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
[TBL] [Abstract][Full Text] [Related]
11. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
[TBL] [Abstract][Full Text] [Related]
12. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP.
Powell TR; Smith RG; Hackinger S; Schalkwyk LC; Uher R; McGuffin P; Mill J; Tansey KE
Transl Psychiatry; 2013 Sep; 3(9):e300. PubMed ID: 24002086
[TBL] [Abstract][Full Text] [Related]
14. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of escitalopram compared to citalopram: a meta-analysis.
Montgomery S; Hansen T; Kasper S
Int J Neuropsychopharmacol; 2011 Mar; 14(2):261-8. PubMed ID: 20875220
[TBL] [Abstract][Full Text] [Related]
16. Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy.
Thibodeau MA; Quilty LC; De Fruyt F; De Bolle M; Rouillon F; Bagby RM
Depress Anxiety; 2015 Mar; 32(3):213-20. PubMed ID: 25069431
[TBL] [Abstract][Full Text] [Related]
17. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
[TBL] [Abstract][Full Text] [Related]
18. Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.
Murck H; Braunisch MC; Konrad C; Jezova D; Kircher T
Int Clin Psychopharmacol; 2019 Jan; 34(1):18-26. PubMed ID: 30300165
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.
Bech P; Tanghøj P; Cialdella P; Andersen HF; Pedersen AG
Int J Neuropsychopharmacol; 2004 Sep; 7(3):283-90. PubMed ID: 15320956
[TBL] [Abstract][Full Text] [Related]
20. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
